Vascular Occlusion: The Filler Complication That Belongs at the Front of the Consent Form

Injectable filler is marketed on its reversibility. That is the entire pitch: a syringe, twenty minutes, and an enzyme that undoes the work if you hate it. The pitch is mostly true, and it is also why the one complication that is not reversible tends to get compressed into a single line on a consent form somewhere between bruising and asymmetry. Filler injected into or against an artery blocks blood flow to whatever that artery feeds. Downstream, tissue dies. If the vessel involved connects to the ophthalmic circulation, the tissue that dies can be retina. The literature on this is not speculative, the case reports have been accumulating for two decades, and the honest version of the consent conversation sounds different from the brochure.

What actually happens when filler meets an artery

The short answer: filler either enters the vessel and travels as an embolus, or it compresses the vessel from outside, and both mechanisms end in ischemia of the tissue that artery supplies.

The intravascular version is the one that produces the dramatic outcomes. Injecting under pressure into an arterial lumen pushes a plug of gel forward. If enough pressure is applied against the direction of flow, product can travel backward through the vessel and then wash into a branch it was never near, which is how a syringe placed in the nose or the glabella reaches the retinal circulation. The facial arterial network is densely interconnected with the internal carotid system through the ophthalmic artery and its branches, and those anastomoses do not respect the map an injector is picturing. The extravascular version is less discussed and more common: a large bolus placed in a tight compartment squeezes the vessel shut without ever entering it, and the skin above it dies more slowly but just as completely.

The clinical signs are worth memorizing, because time is the variable that determines outcome. Immediate blanching of the skin, sometimes in a pattern that maps a vascular territory rather than the treated area. Pain that is out of proportion, though pain can be masked entirely by the lidocaine mixed into most modern products, which is exactly why blanching is the more reliable warning. Over hours, a dusky, mottled, net-like discoloration called livedo reticularis. Over days, blistering, then a dark eschar. Ocular involvement announces itself differently and faster: sudden vision loss, often with pain, sometimes with a drooping lid or a frozen eye. Retinal tissue tolerates ischemia for a very short window, on the order of an hour and a half, and reported recovery of meaningful vision after filler-induced retinal artery occlusion is uncommon.

The numbers are small, and they are not zero

The short answer: serious vascular events are rare enough that most injectors will practice for years without seeing one, and common enough that the published case series now runs to hundreds.

The most useful incidence data comes from a study published in JAMA Dermatology in 2021 that surveyed experienced injectors about occlusion events per syringe used. It reported roughly one occlusion per 6,400 syringes when filler was placed with a needle, and roughly one per 40,900 syringes when placed with a blunt cannula. Those two numbers do more work than any marketing claim about a product line. They establish that the event is genuinely uncommon, that instrument choice changes the risk by roughly a factor of six, and that no technique reduces the risk to zero.

The blindness literature is smaller and grimmer. A review in Dermatologic Surgery in 2015 collected 98 published cases of vision loss after facial filler worldwide. An update in Aesthetic Surgery Journal four years later added dozens more, and the authors were explicit that published cases represent a floor rather than a count, since there is no mandatory reporting mechanism and every incentive in a cosmetic practice runs against publication. The FDA has issued its own safety communication on unintentional injection of soft tissue filler into facial blood vessels, which is the closest thing this field has to a regulatory acknowledgment that the risk is structural rather than anecdotal.

One detail in those reviews rearranges how patients should think about product selection. Autologous fat, the treatment patients often assume is safer because it is their own tissue, dominated the early blindness series. Fat cannot be dissolved. There is no enzyme, no antidote, and no reversal. Hyaluronic acid appears more often in recent reports largely because it is now the most-used product by volume, but it is also the only category with a rescue drug.

"

The instrument, the plane, the volume per pass, and the drug in the drawer are the four things that decide how a vascular occlusion ends. The brand on the syringe is not on that list.

"

The risk lives in specific anatomy, not in specific brands

The short answer: the glabella, the nasal dorsum and tip, the nasolabial fold, the forehead, and the temple carry disproportionate risk because their arteries connect to the ophthalmic circulation.

The glabella has been the most-cited danger zone for years, and for good reason. The supratrochlear and supraorbital arteries run superficially there, they are terminal branches of the ophthalmic artery, and the tissue is tight enough that pressure has nowhere to dissipate. The nose is the other high-consequence territory, and its risk has climbed as non-surgical rhinoplasty has become a routine offering. The dorsal nasal artery is another ophthalmic branch, the nasal skin envelope is unforgiving, and the tip has a marginal blood supply even before anyone adds product to it. A previous surgical rhinoplasty raises the stakes further, because scarring redistributes the vasculature into a pattern no anatomy atlas will predict.

None of this makes those areas untreatable. It makes them areas where the operator's training is the entire safety margin, and where the calculus changes if the person holding the syringe learned injection anatomy in a weekend certification course rather than in a residency. That distinction is legal in many jurisdictions and invisible on a website.

What the safety habits actually buy

The short answer: cannulas, small aliquots, low injection pressure, and retrograde placement each shave the probability down, and aspiration, the technique patients hear about most, is the least reliable of the group.

Aspirating before injection means pulling back on the plunger to check for blood. It is intuitive, it is widely taught, and it fails often enough that treating a negative aspiration as clearance is a mistake. Thick gels do not reliably draw blood back through a fine needle in the time an injector waits, the needle tip moves between the aspiration and the injection, and a negative result on a partially occluded lumen means nothing. It is a weak test presented as a safety ritual.

The techniques with better support are less satisfying to describe. A blunt-tipped cannula tends to push vessels aside rather than pierce them, which is what the sixfold difference in the JAMA Dermatology figures reflects. Injecting slowly and with low thumb pressure limits how far any accidental intravascular deposit travels. Depositing small amounts per pass, on the order of a tenth of a milliliter or less in high-risk zones, limits the size of any embolus. Moving the needle while depositing, and placing product on the withdrawal stroke, reduces the odds of sustained delivery into a single lumen. None of these is a guarantee. Together they are the difference between a practice that has thought about this and one that has not.

The honest summary

Vascular occlusion is the reason the reversibility pitch deserves an asterisk. Hyaluronic acid is genuinely dissolvable, and that fact has probably saved more skin than any other development in injectables, but the enzyme only helps if it is in the building, in sufficient quantity, in the hands of someone who recognizes what is happening within minutes rather than at the next-day follow-up. For calcium hydroxylapatite, poly-L-lactic acid, and fat, there is no equivalent rescue at all, which is a consideration that rarely surfaces when those products are pitched as longer-lasting value.

The rational position is not avoidance. Roughly one event per 40,900 cannula-placed syringes is a risk profile most people accept in ordinary life without thinking about it. The rational position is that this is a medical procedure with a low-probability, high-severity failure mode, and it should be evaluated on the same terms as any other: who is doing it, what they know about the anatomy underneath, and what is in the drawer if it goes wrong. An injector who volunteers this conversation before you ask is demonstrating the exact judgment you are paying for. One who treats the question as an insult has answered it.